Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

troy laboratories pty ltd - cephalexin as cephalexin monohydrate - unknown - cephalexin as cephalexin monohydrate antibiotic active 0.0 - active constituent

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra veterinary products (australia) pty. ltd. - cephalexin as cephalexin monohydrate - oral tablet - cephalexin as cephalexin monohydrate antibiotic active 1000.0 mg/tb - antibiotic & related - dog - large - antibiotics - oral, parenteral | escherichia coli (e. coli) | klebsiella spp. | proteus spp. | staphylococcus aureus | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | clavulanic acid sensitive | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | hypermotility | including b-lactamase producin | infected wounds | infections | lactating | mastitis | protozoal infections | pyometra | salmonellosis | sinusitis | systemic bacterial infection

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra veterinary products (australia) pty. ltd. - cephalexin as cephalexin monohydrate - oral tablet - cephalexin as cephalexin monohydrate antibiotic active 600.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - antibiotics - oral, parenteral | escherichia coli (e. coli) | klebsiella spp. | proteus spp. | staphylococcus aureus | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | clavulanic acid sensitive | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | hypermotility | including b-lactamase producin | infected wounds | infections | lactating | mastitis | protozoal infections | pyometra | salmonellosis | sinusitis | systemic bacterial infection

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra veterinary products (australia) pty. ltd. - cephalexin as cephalexin monohydrate - oral tablet - cephalexin as cephalexin monohydrate antibiotic active 200.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - infections of soft cutaneous tissue | infections of the respiratory tract | infections of the skin | infections of the urinary tracts | musculoskeletal conditions | abscesses | acute respiratory infections | anal sacculitis | arthritis | arthrosis | bronchiseptica | bronchitis | bursitis | escherichia coli | external myopathy | fungal | gingivitis | gram negative bacteria | gram positive bacteria | group d streptococcus | inflamation of soft tissues an | klebsiella spp. | osteitis | osteoarthritis | pharyngitis | pneumonia | post-parturient infections | proteus spp. | pseudomonas aeruginosa | pyoderma | septicaemia | staphylococcus spp. | tendon and ligament sprains | tendonitis | tenosynovitis | tonsillitis | traumatic joint and connective | yeast

Estados Unidos - inglés - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - cephalexin (unii: obn7uds42y) (cephalexin - unii:obn7uds42y) - 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules and cephalexin for oral suspension and other antibacterial drugs, cephalexin capsules and cephalexin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradicati

Estados Unidos - inglés - NLM (National Library of Medicine)

carlsbad technology, inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsule, usp is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus, streptococcus pyogenes , and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes bone infections caused by staphylococcus aureus and/or proteus mirabilis genitourinary tract infections, including acute prostatitis, caused by escheric

Estados Unidos - inglés - NLM (National Library of Medicine)

avkare - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes. cephalexin is indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis. cephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin is indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis. cephalexin is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella pneumoniae . to reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs, cephalexin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information is available, this information should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cephalexin is contraindicated in patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs. pregnancy category b there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. reproduction studies have been performed on mice and rats using oral doses of cephalexin monohydrate 0.6 and 1.5 times the maximum daily human dose (66 mg/kg/day) based upon body surface area basis, and have revealed no evidence of impaired fertility or harm to the fetus. cephalexin is excreted in human milk. caution should be exercised when cephalexin is administered to a nursing woman. the safety and effectiveness of cephalexin in pediatric patients was established in clinical trials for the dosages described in the dosage and administration section [ see dosage and administration ( 2.2) ] . of the 701 subjects in 3 published clinical studies of cephalexin, 433 (62%) were 65 and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. this drug is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection [ see warnings and precautions ( 5.4) ]. cephalexin should be administered with caution in the presence of impaired renal function (creatinine clearance < 30 ml/min, with or without dialysis). under such conditions, careful clinical observation and laboratory studies renal function monitoring should be conducted because safe dosage may be lower than that usually recommended [see dosage and administration ( 2.3)] .

Estados Unidos - inglés - NLM (National Library of Medicine)

avpak - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 500 mg - cephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcuspyogenes. cephalexin is indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis . cephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes. cephalexin is indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis . cephalexin is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella pneumoniae . to reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs, cephalexin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information is available, this information should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cephalexin is contraindicated in patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs. pregnancy category b there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. reproduction studies have been performed on mice and rats using oral doses of cephalexin monohydrate 0.6 and 1.5 times the maximum daily human dose (66 mg/kg/day) based upon body surface area basis, and have revealed no evidence of impaired fertility or harm to the fetus. cephalexin is excreted in human milk. caution should be exercised when cephalexin is administered to a nursing woman. the safety and effectiveness of cephalexin in pediatric patients was established in clinical trials for the dosages described in the dosage and administration section [ see dosage and administration ( 2.2) ]. of the 701 subjects in 3 published clinical studies of cephalexin, 433 (62%) were 65 and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. this drug is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection [ see warnings and precautions ( 5.4) ]. cephalexin should be administered with caution in the presence of impaired renal function (creatinine clearance < 30 ml/min, with or without dialysis). under such conditions, careful clinical observation and laboratory studies renal function monitoring should be conducted because safe dosage may be lower than that usually recommended [ see dosage and administration ( 2.3) ].

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - cephalexin as cephalexin monohydrate - oral tablet - cephalexin as cephalexin monohydrate antibiotic active 300.0 mg/tb - antibiotic & related - dog | bitch | castrate | puppy - infections of soft cutaneous tissue | infections of the digestive tract | infections of the respiratory tract | infections of the urinary tracts | osteomyelitis | acute respiratory infections | bronchiseptica | bronchitis | escherichia coli | group d streptococcus | klebsiella spp. | pharyngitis | pneumonia | proteus spp. | pseudomonas aeruginosa | staphylococcus spp. | tonsillitis

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - cephalexin as cephalexin monohydrate - oral tablet - cephalexin as cephalexin monohydrate antibiotic active 600.0 mg/tb - antibiotic & related - dog | bitch | castrate | puppy - infections of soft cutaneous tissue | infections of the digestive tract | infections of the respiratory tract | infections of the urinary tracts | osteomyelitis | acute respiratory infections | bronchiseptica | bronchitis | escherichia coli | group d streptococcus | klebsiella spp. | pharyngitis | pneumonia | proteus spp. | pseudomonas aeruginosa | staphylococcus spp. | tonsillitis